Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety. Objective Published evidence directly comparing GLP-1RAs with other approved treatments for type 2 diabetes (T2D) w…